Brief: Puretech Presents New Data From Phase 2b Open-Label Extension Study Of Deupirfenidone
29/09/2025 08:48
Sept 29 (Reuters) - PureTech Health PLC PRTC.L: PURETECH PRESENTS NEW DATA FROM PHASE 2B OPEN-LABEL EXTENSION STUDY OF DEUPIRFENIDONE (LYT-100), FURTHER SUPPORTING STRONG AND DURABLE EFFICACY AND POTENTIAL TO SERVE AS NEW STANDARD OF CARE IN IPF PURETECH HEALTH PLC - PATIENTS SWITCHING TO DEUPIRFENIDONE ACHIEVED LUNG FUNCTION STABILIZATION WITH FAVORABLE TOLERABILITY PURETECH HEALTH PLC - PHASE 3 TRIAL DESIGN UPDATE EXPECTED Q4 2025 Source text: ID:nBw8KDhHLa Further company coverage: PRTC.L ((Reuters.Briefs@thomsonreuters.com;))